Symptoms and General Pathology

All Conditions

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

Wounds and Injuries

Rare Diseases

Edema

Lung Neoplasms

Respiratory Aspiration

Lung Injury

Pulmonary Edema

Acute Lung Injury

Lung Diseases

Respiratory Tract Diseases

Thoracic Injuries

Acute Graft Versus Host Disease

Acute Respiratory Distress Syndrome

Reproductive Control Agents

Respiratory System Agents

All Drugs and Chemicals

Albuterol

Ipratropium

Bronchodilator Agents

Anti-Asthmatic Agents

Tocolytic Agents

Adrenergic Agents

Adrenergic beta-Agonists

Adrenergic Agonists

Neurotransmitter Agents

Cholinergic Antagonists

Cholinergic Agents

inhalation of salbutamol (5 mg)

ipratropium

Christoph Ellenberger, MD

Background :

Acute lung injury (ALI) occasionally occurs after pulmonary resection and carries a bad prognosis with a high mortality rate ranging from 20 to 100%.

Objectives :

1. to evaluate pre-, intra- and postoperative changes in hemodynamics, oxygenation indices as well as intra- and extravascular lung water using simple thermodilution technique and continuous arterial pressure analysis
2. to test the efficacy of inhaled beta2 -adrenergic agonist versus anticholinergic agents to reduce lung edema in patients undergoing thoracic surgery and in pigs subjected to lipolysacharide-induced ALI.

Design of the research protocol:

* Prospective controlled trial including surgical patients with high risk factors for ALI (n=60) allocated to receive inhaled drugs (randomised, double-blind, cross-over mode).
* Main measurements:

Intra-thoracic blood volume, intra- and extra-vascular lung water, hemodynamic parameters (CO, systolic arterial pressure/flow variations, dPmax, MAP, CVP), oxygenation indices (PaO2/FIO2), ventilatory parameters, clinical outcome data, histochemical and pathological data.

Glossary CO = cardiac output; dPmax = maximal arterial pressure slope; SAP-V = systolic arterial pressure variations; Flow-V = Flow variations; MAP = mean arterial pressure; CVP = central venous pressure; PaO2=arterial oxygen pressure; FIO2= oxygen inspiratory fraction

Material and Methods Patient selection Consecutive patients who require elective lung resection for cancer at the University Hospital of Geneva will be screened for the presence of risk factors for postoperative ALI or hydrostatic lung edema: age \> 60 yrs, history of chronic alcohol consumption (\>60g/day), prior radiation or chemotherapy, cardiac insufficiency (left ventricular ejection fraction \< 40%, or a history of past acute heart failure), coronary artery disease (history of myocardial infarct, Q wave on the ECG, positive stress test or coronary angiogram), recent pneumonia (within 6 weeks of hospital admission), reduced diffusion capacity for carbon monoxide (DLCO \< 60% of predicted values) and predicted postoperative lung perfusion of \< 55% of total lung perfusion. Patients with at least 3 risk factors for postoperative lung edema will be considered eligible for the study. Patients undergoing pneumonectomy or presenting with intracardiac shunts, valvular diseases or aortic abdominal aneurysm will all be excluded as these conditions preclude valid measurements of extravascular lung water volumes. In addition, chronic treatment with inhaled bronchodilators, a history of any adverse reaction to bronchodilators and liver or kidney insufficiencies will be considered exclusion criteria.

This randomized double blind, cross-over study has been approved by the local university hospital ethics committee and written informed consent has been obtained from all selected patients.

The same team of pneumonologists, thoracic surgeons and anesthesiologists/intensive care physicians will be involved in the perioperative medical management. In addition to history and clinical examination, a standardized preoperative assessment includes chest radiography, ECG, pulmonary function testing as well as computed tomography scans and positron emission tomographies of the chest, abdomen and brain. Quantitative lung perfusion/ventilation scanning, brain imaging, maximal aerobic capacity and myocardial stress testing will be performed when appropriate in intermediate-to-high risk surgical candidates.

Operative and anesthetic management Routinely, antimicrobial prophylaxis with cefazoline will be administered for 24 hours and an epidural catheter was inserted at the 4th-5th or at the 5th-6th vertebral interspace. Thoracic epidural anesthesia (TEA) will be initiated preoperatively with the administration of bupivacaïne 0.25% and continued postoperatively with a lower dosage (bupivacaine 0.1%) that was combined with opiates (fentanyl 2 mcg/ml).

Each patient will be equipped with a 4-French femoral artery catheter and an internal jugular venous line that will be connected to a pulse contour cardiac output monitor (PV2024L; Pulsion Medical Systems AG, Munich, Germany).

After anesthesia induction, a left sided double-lumen endotracheal tube will be inserted and pressure support ventilation will be adjusted to optimize gas exchanges and minimize lung hyperinflation with low tidal volume (5-6 ml/kg), high inspiratory oxygen fraction (50-80%) and positive end expiratory pressure levels (PEEP, 4-12 cm H2O). Periodically, lung recruitment maneuvers will also be performed to re-open alveolar collapsed areas. Anesthesia will be maintained by infusing propofol targeted to achieve bispectral electroencephalographic values between 40 and 60. Lung resection with systematic lymph node dissection will be performed through an anterolateral muscle-sparing thoracotomy.

During surgery, intravenous crystalloids (Ringer-lactate solution) will be infused at a rate of 2-3 ml/kg/h and blood losses will be compensated with colloids (poly(0-2-hydroxy-ethyl)amidon, HAES 6%) and with red blood cell concentrates if the hemoglobin levels decreased below 80-90 g/L. At the end of surgery, all patients will be extubated in the operating theater after reversing the residual neuromuscular blockade with anticholinesterase agents. An active physiotherapy program including incentive spirometry, deep diaphragmatic breathing exercises and mobilization will be started in the high-dependency care unit (HDU). A maximal fluid balance of 500 ml per day will be targeted during the first 48 hours after surgery, by limiting fluid intakes including i.v. crystalloids (glucose-saline 0.45% 1 ml/kg/h), i.v. colloids (1/1 compensation of fluid losses through thoracic drains and oral beverages (500 ml on the day of surgery and 1'000-1'200 ml over the next two days).

Study design Within the first 36 hours after surgery, patients will received in random order nebulized salbutamol and nebulized ipratropium bromide at 4 consecutive sessions conducted at least 6 hours apart (figure 1). The treatment order will be generated from random number tables by an independent observer and concealed in sealed envelopes. The investigators, attending physicians and nurses will be blinded to the treatment group.

Over 10 minutes, either salbutamol (5 mg diluted in 5 ml normal saline) or ipratropium bromide (0.5 mg diluted in 5 ml normal saline) will be administered via a Cirrus nebulizer and a compressor (Wokingham, UK).

Measurements In addition to arterial blood sampling, complete sets of hemodynamic measurements will be performed as shown in figure 1: (a) preoperatively, before and 30 min after initiation of TEA, (b) 2 and 8 hours after surgery (postoperative day 0, \[POD0\]), before and 30 min after administration of salbutamol or ipratropium (6 hours apart in random order), (c) on the morning of the first postoperative day (POD1) on two consecutive sessions (6 hours apart in random order), before and 30 min after administration of salbutamol or ipratropium bromide.

Cardiac output (CO) and volumetric pulmonary variables will be obtained by the simple transpulmonary indicator dilution technique. Three consecutive measurements with less than 10% variations will be averaged. A fifteen milliliters bolus of 0.9% saline at 4°C will be injected through the central venous catheter into the right atrium and the change in temperature will be measured with the femoral artery thermistor tipped catheter. Using the mean transit time methods, intrathoracic blood volume, extravascular lung water and global end-diastolic volume will be calculated and indexed for the patient body weight (ITBVI, EVLWI and GEDVI, respectively). Heart rate (HR), stroke volume (SV) and maximal change in arterial pressure will be determined by beat-to-beat analysis of the arterial pressure wave. The systemic vascular resistance index (SVRI) will be calculated using standard formula. The ratio of EVLWI to ITBVI will be calculated as an index reflecting the permeability of the alveolar-capillary barrier.

Arterial oxygen pressure (PaO2 in mmHg) will be measured using a blood gas analyzer (ABL-510 analyzer, Radiometer, Copenhagen, Denmark) and will be related to the inspiratory O2 fraction to express the oxygenation index (PaO2/FIO2). In addition, chest radiograph scores (number of quadrants with \>50% involvement with an alveolar filling process) will be recorded on POD0 (arrival in HDU) and POD1 (end of the study).

Outcomes The primary outcome measure will be a reduction in EVLWI within the first 24 hours after lung surgery. Secondary outcomes will be the PaO2/FIO2 ratio, hemodynamic data and radiological lung injury score.

Statistical analysis A sample size of 20 subjects provides the power (80%) to detect a 20% difference in EVLWI for a two-sided significance level of  = 0.05; in a preliminary study, we found a mean value of 9.1 ml/kg for EVLWI with a standard deviation (SD) of 2.2 ml/kg.

Results will be reported as M(SD), median (interquartile) or numbers (percentages). A p value of \< 0.05 was considered significant in all analyses. All data will be analyzed with the SPSS statistical software (version 9.0, SPP, Chicago, IL). ANOVA for repeated measurements will be used to compare baseline values (preoperative, POD0 and POD1) followed by Bonferroni post-hoc tests. Paired and unpaired Student t tests will be used to assess and to compare the effects of bronchodilators. Furthermore, the correlation between changes in EVLWI, CI, ITBVI and PaO2/FIO2 will be analyzed by linear regression.

Prevention of Lung Edema After Thoracic Surgery

Does Inhaled Salbutamol Prevent Lung Edema After Thoracic Surgery? A Randomized Controlled Study

University Hospital, Geneva

Diseases and Abnormalities at or Before Birth

Infections

Immune System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Syndrome

Necrosis

Respiratory Distress Syndrome

Respiratory Distress Syndrome, Newborn

Bronchiolitis

Bronchiolitis Obliterans Syndrome

Bronchiolitis Obliterans

Respiration Disorders

Premature Birth

Infant, Premature, Diseases

Infant, Newborn, Diseases

Bronchitis

Communicable Diseases

Respiratory Tract Infections

Bronchial Diseases

Lung Diseases, Obstructive

Pneumonia

Organizing Pneumonia

Graft vs Host Disease

Respiratory Distress Syndrome, Infant

Bronchiolitis Obliterans Organizing Pneumonia

Homologous Wasting Disease

Anti-Inflammatory Agents

Antirheumatic Agents

Analgesics

Gastrointestinal Agents

Etanercept

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Immunosuppressive Agents

Immunologic Factors

Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.

Gregory A Yanik, MD

The purpose of this study is to determine the effectiveness of etanercept in the treatment of patients with sub-acute lung injury following a bone marrow transplant. This study will also examine the toxicity of treatment with etanercept as well as whether there is an improved quality of life in these patients.

Lung or breathing problems can develop several months to years following a bone marrow transplant. In some cases, these breathing problems develop without any signs of germs or infection in the lungs. The name for this type of breathing problem is called "Sub-Acute Lung Injury". Sub-acute lung injury often develops many months, even years following a bone marrow transplant. It is often characterized by shortness of breath, cough, wheezing and fatigue.

Sub-acute lung injury can either lead to the formation of scar tissue in the lungs (making it difficult to take deep breaths), or it can cause the lungs to get weak (making people feel out of breath easily). Approximately 25 - 50% of patients with sub-acute lung injury may eventually die from the damage in their lungs. Typically, such patients die from infections that develop inside the damaged lungs.

In this study, treatment with an experimental drug called Etanercept will be used. (Enbrel). The physicians feel there is the possibility that Etanercept may help improve breathing. Breathing ability will be assessed prior to treatment as well as during and after treatment so that comparisons can be made.

Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant

Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Sub-Acute Pulmonary Dysfunction Following Allogeneic Stem Cell Transplantation. A Phase II Study

Response was defined as a greater than or equal to 10% improvement in the absolute value for FEV1 (for obstructive defects) or FVC (for restrictive defects), and DLCO (Diffusing Capacity of the Lungs for Carbon Monoxide) .

To evaluate the toxicity of etanercept therapy in patients with sub-acute lung injury \> 100 days post transplant, the percent incidence of grade 3 to 4 adverse events among evaluable patients was calculated.

University of Michigan Rogel Cancer Center

Serious Adverse Events (SAEs) are defined as Grade 4 or 5 (Adverse events will use the descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0.) non-pulmonary toxicities.

Etanercept for lung injury

Etanercept: Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.

Etanercept Treatment

Age, Continuous

Sex: Female, Male

AML/MDS/MF

Acute Lymphoblastic Leukemia (ALL)

Chronic Mylogenous Leukemia (CML)

NHL/CLL

Myeloma

Nonmalignant

Diagnosis

HLA Matched

Mismatch

Human Leukocyte Antigen (HLA) Match

Pluripotent Stem Cell (PSC)

Marrow

Cell Source

Matched Related Donor (MRD)

Unrelated Donor (URD)

Donor Type

Chronic Graft Versus Host Disease (GVHD) Present

Restrictive

Obstructive

Lung Injury Pattern

All patients enrolled that received at least one scheduled dose.

Gregory Yanik, M.D.

≥10% Improvement in FEV1 / FVC

≥10% Improvement in DLCO

34 subjects were enrolled. Thirty-one of 34 subjects were evaluable for response, with three subjects completing \<50% of scheduled dosing.

Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, or FVC, and DLCO

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Prevention of Lung Edema After Thoracic Surgery	NCT00498251	Lung Injury, Ac... Thoracotomy Anesthesia Intensive Care,... Extravascular L...	inhalation of s... ipratropium	-	University Hospital, Geneva
Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant	NCT00141726	Lung Injury, Ac... Respiratory Dis... Bronchiolitis O...	Etanercept	6 Years -	University of Michigan Rogel Cancer Center

Spots Global Cancer Trial Database for lung injury, acute